Sponsors (3)
This bill improves drug supply-chain transparency, recall speed, and consumer access to manufacturer information—especially benefiting patients and health systems—but does so at the cost of higher compliance and IT burdens for industry and regulators, potential proprietary/security exposures, and some erosion of customs-origin transparency that could affect trade enforcement and prices.
Patients and health systems can more quickly identify original manufacturers and specific production sites for active ingredients and finished drugs, making source tracing and product recalls faster and more effective.
Consumers (patients and caregivers) can access manufacturer and quantity information via QR/barcode links or paper on request, enabling more informed purchases and verification of drug origin.
Drug manufacturers and importers can follow FDA labeling rules (instead of separate customs marking rules) for finished imported drugs, simplifying compliance and paperwork for imports.
Small and mid-size manufacturers and distributors face higher compliance costs (labeling, recordkeeping, IT), which could be passed to consumers as higher drug prices or reduce market competition.
Manufacturers and regulators will incur administrative and IT burdens (searchable portals, QR linkage, extra paperwork) during implementation and ongoing operations, creating transition costs and workload.
Allowing FDA labeling to substitute for customs marking could reduce uniform country-of-origin information for customs officials, complicating tariff administration and trade statistics.
Based on analysis of 3 sections of legislative text.
Requires labels/certificates to disclose original API manufacturers, facility names/locations, and unique facility IDs; allows FDA labeling to satisfy certain customs marking rules.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Introduced April 14, 2026 by Rich McCormick · Last progress April 14, 2026
Requires drug makers, packers, and distributors to include detailed supply-chain labeling for finished drug products and active pharmaceutical ingredients (APIs). Labels (or a scannable link to a searchable portal) must identify the original manufacturer for each API and the facility information (name, place of business, and unique facility identifier) for manufacturers/packers/distributors; the Secretary must issue implementing regulations that apply no earlier than one year after final rule publication. The bill also lets qualifying finished drug products meet U.S. customs marking rules by complying with the new FDA labeling standard instead of general country-of-origin marking requirements.